Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.

Nevertheless, prasugrel was previously noted to have a strong trend towards major bleeding including ICH in patients ≥75 years old and a related boxed warning was issued. 6 Since age is generally known as an important risk factor for ICH in patients on anti-platelet therapy, 38 future studies are needed to ensure the safety of intensification of antiplatelet therapy in elderly patients.

also in 5,725 other papers